Every one of those 1 sits in a single category, health-it. Of the tracked stories, 1 of 1 also mention Kiwis, the most common co-covered peer. Their average consequence score of 7 runs above the beat's 5.8 for that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Genomic Trial
Every one of those 1 sits in a single category, health-it. Of the tracked stories, 1 of 1 also mention Kiwis, the most common co-covered peer. Their average consequence score of 7 runs above the beat's 5.8 for that window. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. Genomic Trial appears in 1 tracked Healthcare story from March 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 24 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Genomic Trial. Shared-story counts are live from our verified record — not editorial picks.
New Zealand has initiated a landmark genomic trial designed to bring advanced diagnostic testing onshore for patients with cancer and rare disorders. The program aims to reduce the 'diagnostic odyssey' by eliminating the need to send biological samples to overseas laboratories.